ViiV Offers Entire HIV/AIDS Portfolio To Generic Firms In Low-Income Countries, No Royalties Attached
This article was originally published in The Pink Sheet Daily
Executive Summary
With the problem of public access to medicines largely overcome, the new challenge is to get the more high-tech therapies to people with HIV/AIDS in the least developed countries, a spokeswoman said.